Victor Grifols Deu
Director/Board Member presso GRIFOLS, S.A.
Patrimonio netto: 131 654 $ in data 31/03/2024
Profilo
Attualmente, Victor Grifols Deu occupa la posizione di Joint Chief Executive Officer & Executive Director di Grifols SA. Il signor Deu è anche nel consiglio di Araclon Biotech SL. Ha conseguito una laurea presso l'Institut Qumic De Sarri e un MBA presso la UCD Michael Smurfit Graduate School of Business.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
GRIFOLS, S.A. CLASS A
0.00% | 31/12/2022 | 14 620 ( 0.00% ) | 131 654 $ | 31/03/2024 |
Posizioni attive di Victor Grifols Deu
| Società | Posizione | Inizio |
|---|---|---|
| GRIFOLS, S.A. | Director/Board Member | 30/05/2016 |
Araclon Biotech SL
 Araclon Biotech SL Miscellaneous Commercial ServicesCommercial Services Araclon Biotech SL researches and develops therapies and diagnostic methods for Alzheimer’s disease. Its research areas include early diagnosis of Alzheimer’s disease; therapy for Alzheimer’s disease; development of a predictive test for the Alzheimer’s disease in asymptomatic individuals; and development of therapy for Parkinson’s disease. The company was founded on January 27, 2004 and is headquartered in Zaragoza, Spain. | Director/Board Member | - |
Formazione di Victor Grifols Deu
| UCD Michael Smurfit Graduate School of Business | Graduate Degree |
| Institut Químic De Sarrià | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| GRIFOLS, S.A. | Health Technology |
| Aziende private | 1 |
|---|---|
Araclon Biotech SL
Araclon Biotech SL Miscellaneous Commercial ServicesCommercial Services Araclon Biotech SL researches and develops therapies and diagnostic methods for Alzheimer’s disease. Its research areas include early diagnosis of Alzheimer’s disease; therapy for Alzheimer’s disease; development of a predictive test for the Alzheimer’s disease in asymptomatic individuals; and development of therapy for Parkinson’s disease. The company was founded on January 27, 2004 and is headquartered in Zaragoza, Spain. | Commercial Services |
- Borsa valori
- Insiders
- Victor Grifols Deu
